QUEBEC CITY -- Infectio Diagnostic Inc. (IDI), a Quebec biotechnology company, has just submitted its ultra-rapid screening test for methicillin-resistant Staphylococcus aureus (MRSA) to the Food and Drug Administration (FDA) and to Health Canada for their authorization for sale.
MRSA is one of the most important causes of infection in hospitals. The dissemination, often resulting from contaminated hands of someone carrying Staphylococcus aureus, can spread very rapidly. Furthermore, the incidence of MRSA infections is increasing almost everywhere in the world. The consequences can be severe (high rates of mortality and morbidity). Also, the use of antibiotics and extended hospitalization required to treat the infection can be very expensive. It has been demonstrated in a number of countries that the best way to control MRSA infections in hospitals is through regular, rapid screening.
The new test developed by IDI will enable detection of MRSA in one hour, whereas existing methods require two to three days. This is the only known test that enables immediate diagnosis. This test will help control MRSA infections, considerably reduce the cost of treatment with antibiotics, and limit the need for isolation to only those patients presenting a real risk. This product will be commercialized as soon as IDI receives authorization from the regulatory agencies.